Weekly Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings on Jan 14, 2019

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Corporate Logo
During 2018 Q3 the big money sentiment increased to 1.09. That’s change of 0.05, from 2018Q2’s 1.04. 7 investors sold all, 15 reduced holdings as Infinity Pharmaceuticals, Inc. ratio increased. 13 grew stakes while 11 funds bought stakes. Funds hold 29.50 million shares thus 7.01% more from 2018Q2’s 27.57 million shares.
Opaleye Mgmt Inc accumulated 275,000 shs. California Pub Employees Retirement holds 0% of its capital in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 88,100 shs. Panagora Asset Mgmt stated it has 0% of its capital in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Citadel Advsrs Lc holds 0% of its capital in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 35,878 shs. Millennium has 94,310 shs. Massachusetts-based State Street Corporation has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Clear Harbor Asset Mgmt Ltd holds 97,630 shs or 0.04% of its capital. The New York-based Qs Investors Lc has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Wellington Mgmt Gru Ltd Liability Partnership holds 0% or 1.56M shs in its capital. Blackrock has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). The Ontario – Canada-based Royal Savings Bank Of Canada has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). First Eagle Invest Management Ltd Liability owns 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 500,000 shs. Ecor1 Capital Lc owns 462,068 shs. 292 were accumulated by Bnp Paribas Arbitrage Sa. Dimensional Fund Advisors Limited Partnership invested in 0% or 1.07 million shs.

Infinity Pharmaceuticals, Inc. registered $3.53 million net activity with 4 buys and 2 insider sales since August 15, 2018. On Wednesday, August 15 Shares for $28,687 were sold by Kutok Jeffery. Another trade for 5,000 shs valued at $14,100 was made by Perkins Adelene Q on Monday, October 1.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Coverage

In total 3 analysts cover Infinity Pharmaceuticals (NASDAQ:INFI). “Buy” rating has 1, “Sell” are 1, while 1 are “Hold”. 33% are bullish. 3 are the (NASDAQ:INFI)’s analyst reports since November 12, 2018 according to StockzIntelligence Inc. On Monday, November 12 the firm has “Underweight” rating given by JP Morgan. On Monday, November 12 the rating was downgraded by Wells Fargo to “Market Perform”. Listed here are Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) PTs and latest ratings.

04/01/2019 Broker: FBR Capital Rating: Buy New Target: $3 Initiates Coverage On
12/11/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Downgrade
12/11/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

INFI is reaching $1.32 during the last trading session, after increased 0.76%.Currently Infinity Pharmaceuticals, Inc. is downtrending after 36.36% change in last January 14, 2018. INFI has 7,650 shares volume. INFI underperformed by 36.36% the S&P 500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States.The firm is valued at $75.06 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study.Last it reported negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Another two news for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) were briefly announced by: Finance.Yahoo.com on December 21, 2018 with title “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News”. The other Zacks.com‘s article was titled “Is Home Depot (HD) Poised to Beat Earnings Estimates in Q3? – Zacks.com” and announced on November 06, 2018.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.